Share on StockTwits
 

Piper Jaffray increased their price objective on shares of Horizon Pharma (NASDAQ:HZNP) from $7.00 to $17.00 in a research note issued on Monday, StockRatingsNetwork.com reports. Piper Jaffray’s target price indicates a potential upside of 69.83% from the company’s current price.

Horizon Pharma (NASDAQ:HZNP) traded down 1.20% during mid-day trading on Monday, hitting $9.8901. 200,555 shares of the company’s stock traded hands. Horizon Pharma has a one year low of $1.97 and a one year high of $10.68. The stock has a 50-day moving average of $8.72 and a 200-day moving average of $5.22. The company’s market cap is $651.3 million.

A number of other firms have also recently commented on HZNP. Analysts at Zacks downgraded shares of Horizon Pharma from an “outperform” rating to a “neutral” rating in a research note on Wednesday, February 5th. They now have a $10.60 price target on the stock. Separately, analysts at JMP Securities raised their price target on shares of Horizon Pharma from $10.00 to $16.00 in a research note on Thursday, January 30th. They now have an “outperform” rating on the stock. Finally, analysts at R. F. Lafferty raised their price target on shares of Horizon Pharma from $9.00 to $11.00 in a research note on Wednesday, January 29th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $12.43.

Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.